University of California

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
月曜日, 5月 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
木曜日, 5月 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

BASF and University of California, Berkeley, celebrate their successful 10-year collaboration

Retrieved on: 
火曜日, 4月 23, 2024
Stanford University, University of Southern California, University, University of California, Irvine, BASF, Research, Partnership, University of California, History, AFL–CIO, Patent, Chemistry, University of California, Berkeley, Ministry of Energy, Associate, UC, California Institute of Technology

The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.

Key Points: 
  • The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.
  • To mark the anniversary, BASF and CARA hosted a scientific symposium on sustainable transformation in chemistry on April 22.
  • Since 2014, the collaboration has expanded to 11 California universities, including UC Santa Barbara, UC Irvine as well as Stanford University, California Institute of Technology, and University of Southern California.
  • More than 80 faculty members and 170 postdocs/graduate students have worked with BASF and CARA, and BASF has hired 11 postdocs/students from the CARA community.

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
水曜日, 5月 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Clinical Trial by Harvard Pilgrim Health Care Institute, HCA Healthcare, UCI Health and CDC Identifies Strategy to Rapidly Detect and Respond to Hospital Outbreaks Using Algorithm-Driven Technology

Retrieved on: 
火曜日, 4月 23, 2024
Data Management, Other Health, Technology, Managed Care, General Health, Infectious Diseases, Hospitals, Clinical Trials, Other Technology, Biotechnology, Science, Software, Networks, Other Science, Research, Health, University, Hospital, Risk, CDC, University of California, HCA Healthcare, Patient safety, Fungal infection, Doctor of Science, Patient, MPH, UCI, NEJM, Harvard Medical School, Infection, Harvard Pilgrim Health Care, Doctor of Public Health, Senior advisor, COVID-19, CLUSTER, Vaccine

The large multi-state, real-world study was conducted in 82 hospitals and led by Harvard Pilgrim Health Care Institute, HCA Healthcare, University of California, Irvine (UCI) Health and the Centers for Disease Control and Prevention (CDC).

Key Points: 
  • The large multi-state, real-world study was conducted in 82 hospitals and led by Harvard Pilgrim Health Care Institute, HCA Healthcare, University of California, Irvine (UCI) Health and the Centers for Disease Control and Prevention (CDC).
  • While hospitals and health systems work to prevent infections and reduce the opportunity for outbreaks to occur, there is no standardized approach for detecting transmission.
  • Early detection can lead to a rapid response that reduces the chance for outbreaks to occur.
  • “The CLUSTER trial provides evidence that early detection powered by automation tools and quick action can prevent outbreaks from growing."

Nancy Krystal Joins Velo3D as Vice President, General Counsel

Retrieved on: 
木曜日, 4月 11, 2024
Electronic Design Automation, Machine Tools, Metalworking & Metallurgy, Engineering, Technology, Manufacturing, Software, Hardware, Sale, Law, University, Candy, General counsel, University of California, VLD, M&A, Big Heart Pet Brands, Jelly Belly, Growth, Management

Velo3D , Inc. ( NYSE: VLD ), a leading additive manufacturing technology company for mission-critical metal parts, today announced the appointment of Nancy Krystal as Vice President, General Counsel to oversee all legal matters for the company.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading additive manufacturing technology company for mission-critical metal parts, today announced the appointment of Nancy Krystal as Vice President, General Counsel to oversee all legal matters for the company.
  • With over 16 dynamic years of experience in corporate law, Nancy brings a wealth of experience in navigating complex legal landscapes and spearheading pivotal deals to her new role at Velo3D.
  • View the full release here: https://www.businesswire.com/news/home/20240411950967/en/
    With over 16 dynamic years in corporate law, Nancy has navigated the legal landscape with finesse, spearheading pivotal deals and ensuring compliance at every turn.
  • As General Counsel of Jelly Belly Candy Company, she orchestrated the historic sale of the company, showcasing her strategic acumen and leadership.

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

Retrieved on: 
木曜日, 4月 18, 2024
Harvard University, University, Genetics, Post-traumatic stress disorder, Meta-analysis, Fear, Broad Institute, Eurosport 1, Neuroscience, Cognition, PTSD, Chairperson, Trauma, Hand, University of California, Genetic variation, Doctor of Philosophy, Research, URL, Life, Axon guidance, Native, Survivor, Therapy, SURFnet, Mental health, Psychiatric Genomics Consortium, DSM-IV codes, Psychiatric Genetics (journal), Nature Genetics, MIT, Genome, Diagnosis, Biology, NIMH, Synapse, Frequency response, Meat

NEW YORK, April 18, 2024 /PRNewswire/ -- The Global PTSD Genetics initiative founded in 2015 by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Research at Broad Institute, and the Psychiatric Genomics Consortium today announces a pivotal milestone in the genetics of post-traumatic stress disorder (PTSD) has been achieved and published in Nature Genetics on April 18,2024.

Key Points: 
  • Convergent multiomic approaches identified 43 potential causal genes, including modulators of neurotransmitters, ion channels, axon guidance, and synapses.
  • Additional top genes influence stress, immune, fear, and threat-related processes, previously hypothesized to underlie PTSD neurobiology.
  • These findings strengthen the understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
  • Posttraumatic stress disorder (PTSD) is characterized by intrusive thoughts, hyperarousal, avoidance, and negative alterations in cognition and mood that can become persistent for some individuals after traumatic event exposure.

Renowned Alzheimer's Neurologist Dale Bredesen, MD, Joins Pacific Neuroscience Institute

Retrieved on: 
火曜日, 4月 16, 2024
UCLA, Neurodegenerative disease, Alzheimer's disease, Duke University Hospital, Brain, University, Dementia, Recode, Hope, NIH, Risk, Arrest, University of California, PNI, Doctor of Philosophy, The New York Times, Research, Trial of the century, History, Confusion, Exercise, Documentation, Ageing, UCSF, Buck, Patient, Survivor, Neurology, Medicine, Faculty, Amnesia, Quality of life, Nobel, UC, Nursing

SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®. Over the past four months, as the senior director of the nascent Precision Brain Health program, he and his colleagues have been intensely focused on developing what promises to be the world's first formalized system to comprehensively address neurodegenerative disease in the world. While not quite ready for primetime, the excitement around the clinical implications for patients is palpable.

Key Points: 
  • SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.
  • Taking a personalized, biological systemwide approach and becoming proactive about interventions, represent the first steps towards stopping Alzheimer's in its tracks."
  • Pacific Neuroscience Institute has a history of innovation that fits perfectly with the development of this novel program."
  • He directed the Program on Aging at the Burnham Institute and joined the Buck Institute as founding president and CEO.

Juice Beauty Announces Patent Pending Sagrantino SuperGrape Ingredient Infusion Across Best-Selling Anti-Wrinkle Stem Cellular Skincare Collection

Retrieved on: 
火曜日, 4月 16, 2024
University, Customer, Wine, Animal, Skin, Sustainability, University of California, Human, Doctor of Philosophy, Water, Environment, Sagrantino, Nitrogen, Patent, Farm, Chemistry, Petroleum, Hyaluronic acid, Beauty, Ethanol, Cosmetics

The Sagrantino grapevine was originally brought to the Juice Beauty Farm from the Umbria region of central Italy. This rare high antioxidant SuperGrape is only grown on a few farms in North America and mostly for wine -- however starting in 2018, Founder Karen Behnke and her husband, Howard Luria, M.D., began experimenting with ways to boost the already packed antioxidant grape to even higher levels, including updating the farming techniques to maximize the yield for higher phenol antioxidant measurements.   Specific methods were deployed of planting nitrogen rich red clover between the vines, removing sugar and ethanol through a clean reverse osmosis membrane process, exposing the vines to sun differently and more.  The patent pending discovery with an incredibly high ORAC and phenol levels, makes the grape a powerful and strong inhibitor of free radical mediated reactions and can be advantageously used to prevent or slow the appearance of skin aging.

Key Points: 
  • Juice Beauty has developed the rare Sagrantino SuperGrape, grown on the Juice Beauty certified organic farm in Healdsburg, California, and created a harvesting and fermentation technology to extract and deliver one of the highest antioxidant levels found in skincare products.
  • This powerful technology and ingredient were first utilized in Juice Beauty's SuperGrape Youth Renew Serum with Hyaluronic Acid and now this ingredient has been infused across the entire Anti-Wrinkle Stem Cellular skincare line, supercharging it with this 3x antioxidant power ingredient.
  • The Sagrantino grapevine was originally brought to the Juice Beauty Farm from the Umbria region of central Italy.
  • Starting this month, Juice Beauty has further enhanced the best-selling Anti-Wrinkle Stem Cellular skincare line with this patent-pending antioxidant Sagrantino SuperGrape to achieve even higher levels of glowing, healthier-looking skin.

Is Universal Healthcare A Solution to U.S. Healthcare Disparities? The Binaytara Foundation Hosts a Debate on this Crucial Topic with Global Leaders

Retrieved on: 
木曜日, 4月 11, 2024
Health equity, Hematology, University of California, Doctor of Philosophy, Health, Senate, Legislation, Private sector, Associate, Duke University, Bone marrow, Physician, Summit, American Medical Association, American Cancer Society, Transport, Justice Select Committee, ACS, Binaytara Foundation, Master of Science, MPH, Consultant, Organization, University, Cancer, American College, Way, Policy, Health care, Deportation, Plague, Patient, MBA, Internal medicine, FACP

BELLEVUE, Wash., April 11, 2024 /PRNewswire-PRWeb/ -- The Binaytara Foundation, a leading non-profit organization dedicated to promoting health equity and addressing healthcare disparities, is pleased to announce an upcoming debate on the topic: "Is Universal Healthcare A Solution to U.S. Healthcare Disparities?" The debate will be held April 28, during The Summit on Cancer Health Disparities (SCHD24), which will take place in Seattle from April 26 to 28, 2024.

Key Points: 
  • Healthcare disparities continue to plague communities across the United States, and the globe disproportionately affecting marginalized and underserved populations.
  • As the nation grapples with how to address these disparities, the debate on the efficacy of universal healthcare has taken center stage.
  • The Binaytara Foundation recognizes the importance of engaging in thoughtful discourse on this critical issue and is bringing together global leaders, healthcare experts, policymakers, and advocates to explore the potential of universal healthcare in addressing healthcare disparities in the United States at its summit.
  • How might universal healthcare affect medical innovation and the development of new treatments and technologies in the U.S. healthcare system?